Libra Therapeutics Appoints Philip Lambert, Ph.D., as Chief Scientific Officer
SAN DIEGO -- Libra Therapeutics, Inc. today announced the appointment of Philip Lambert, Ph.D., as the company’s first CSO. With more...
Search
- Sep 23, 2020
Libra Launches with $29M Series A to Develop Novel Therapeutics for Neurodegenerative Diseases
Libra launched with $29M to develop novel drug candidates focused on restoring the cellular balance lost in neurodegenerative diseases.